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Abstract
The hepatotoxicity of bromobenzene (BB) is directly related to the covalent binding of both
initially formed epoxide and secondary quinone metabolites to at least 45 different liver proteins.
4-Bromophenol (4BP) is a significant BB metabolite and a precursor to reactive quinone
metabolites, yet when administered exogenously it has negligible hepatotoxicity compared to BB.
The protein adducts of 4BP were thus labeled as non-toxic (Monks, T. J.; Hinson, J. A.; Gillette, J.
R. (1982) Life Sci. 30, 841–848). To help identify which BB-derived adducts might be related to
its cytotoxicity, we sought to identify the supposedly non-toxic adducts of 4BP and eliminate them
from the BB target protein list. Administration of [14C]-4BP to phenobarbital-induced rats resulted
in covalent binding of 0.25, 0.33 and 0.42 nmol-eq 4BP/mg protein in the mitochondrial,
microsomal and cytosolic fractions, respectively. These values may be compared to published
values of 3–6 nmol/mg protein from a comparable dose of [14C]-BB. After subcellular
fractionation and 2D electrophoresis, 47 radioactive spots on 2D gels of the mitochondrial,
microsomal and cytosolic fractions were excised, digested and analyzed by LC-MS/MS. Twenty
nine of these spots contained apparently single proteins, of which 14 were non-redundant. Nine of
the 14 are known BB targets. Incubating freshly-isolated rat hepatocytes with 4BP (0.1–0.5 mM)
produced time- and concentration-dependent increases in lactate dehydrogenase release and
changes in cellular morphology. LC-MS/MS analysis of the cell culture medium revealed rapid
and extensive sulfation and glucuronidation of 4BP as well as formation of a quinone-derived
glutathione conjugate. Studies with 7-hydroxycoumarin (7HC), (−)-borneol or D-(+)-
galactosamine (DGN) showed that inhibiting the glucuronidation/sulfation of 4BP increased the
formation of a GSH-bromoquinone adduct, increased covalent binding of 4BP to hepatocyte
proteins and potentiated its cytotoxicity. Taken together, our data demonstrate that protein
adduction by 4BP metabolites can be toxicologically consequential, and provide a mechanistic
explanation for the failure of exogenously administered 4BP to cause hepatotoxicity. Thus the
probable reason for the low toxicity of 4BP in vivo is that rapid conjugation limits its oxidation
and covalent binding and thus its toxicity.
Introduction
The hepatotoxicity of bromobenzene (BB), first reported in 1935,1 was shown by Brodie et
al.2 to stem from the covalent binding of chemically reactive metabolites to hepatocellular
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proteins. Subsequent work in several laboratories demonstrated that pretreatment of rats
with phenobarbital accelerates BB metabolism and its glutathione-depleting activity,
increases the rate and extent of its protein covalent binding and potentiates its hepatotoxicity
both in vivo and in isolated rat hepatocytes.3–6 Based on the structures of known stable
metabolites of BB (Scheme 1) it was proposed that BB-3,4-oxide (2) was the critical
reactive intermediate that covalently bound to proteins leading to cytotoxicity. Although
BB-3,4-oxide has never been isolated or synthesized, its intermediacy in BB metabolism and
covalent binding is strongly supported by the isolation of 3–7 as BB metabolites.7–9
Analogous studies with chlorobenzene10 and naphthalene11, 12 have provided additional
support for arene oxides as critical cytotoxic metabolites.
4-Bromophenol (4BP) is a major metabolite of bromobenzene.7 It is derived primarily by
the rapid non-enzymatic rearrangement of BB-3,4-oxide13 Microsomal metabolism studies
of 4BP,14 naphthol15 and phenol16 have shown that phenols are efficiently activated to
protein covalent binding species, probably quinones. These observations naturally raised a
question about the relative ability of quinone binding vs. epoxide binding to cause
cytotoxicity. To address this question, Monks et al.17 compared the protein covalent binding
and hepatotoxicity of BB vs. 4BP in non-induced rats. They found that at equimolar doses,
4BP bound 62% as much as BB, yet only BB caused hepatotoxicity. From this they
concluded that the hepatotoxic effects of BB derive mainly from its 3,4-oxide metabolite
and that 4BP metabolites were non-toxic despite their ability to covalently modify proteins.
From the 1970s through the 1990s, as the amount of information linking covalent binding to
cytotoxicity grew, attention began to shift away from the identity and chemistry of small
molecule electrophiles toward the identity and significance of the individual protein targets
to which they bind.18 In an attempt to gain insight into cellular mechanisms of reactive
metabolite toxicity, our laboratory has identified numerous hepatocellular proteins that
become covalently labeled by metabolites of [14C]-BB.19–21 It was thus of interest to
identify proteins targeted by reactive metabolites of 4BP since these adduction events are
not associated with hepatotoxic consequences.17 It was thought that their identification as a
specific subset of proteins targeted by BB metabolites could help focus attention on those
targets that are unique to BB and thus more likely to be more directly associated with
cytotoxicity.
To this end we treated phenobarbital-induced rats with [14C]-4BP, isolated liver subcellular
fractions, separated radioactive proteins by 2D gel electrophoresis, and identified the
proteins in radioactive spots by tryptic digestion and mass spectrometry. Although the total
amount of [14C]-4BP binding was low compared to that usually observed with BB, we
identified 29 proteins (14 non-redundant) in single-protein spots, nine of which were
previously known BB targets. The unexpectedly low binding of 4BP metabolites in vivo
prompted us to re-examine the earlier literature on this subject and to re-evaluate the relative
toxicity of BB and 4BP experimentally using isolated hepatocytes. Our observations suggest
that the low toxicity of 4BP may actually stem from its much lower level of metabolic
activation and covalent binding relative to BB, and that this in turn may be due to the rapid
removal of 4BP via glucuronidation and sulfation. In support of this hypothesis we
demonstrate herein that when the latter processes are inhibited, the covalent binding and
cytototoxicity of 4BP are both significantly potentiated.
Materials and Methods
Materials
4-Bromophenol, (−)-borneol, D-(+)-galactosamine (DGN), umbelliferone (7-
hydroxycoumarin, 7HC), 4-vinylpyridine, phenylmethylsulfonyl fluoride (PMSF),
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collagenase type IV and Percoll were from Sigma-Aldrich (www.sigmaaldrich.com/). HPLC
grade solvents and analytical grade inorganic salts were obtained from Fisher
(www.fishersci.com). Dulbecco’s Modified Eagle Medium (DMEM) and phosphate
buffered saline (PBS, pH 7.4) were purchased from Cellgro (www.cellgro.com), Williams’
Medium E (WME) was purchased from Gibco-Invitrogen (www.invitrogen.com), and
lactate dehydrogenase (LDH) assay kits were purchased from Takara-Bio
(www.clontech.com/takara). Sequencing grade trypsin was obtained from Roche
(www.rocheusa.com). Sequenal grade urea and CHAPS were obtained from Pierce
Biotechnology (www.piercenet.com). Tris, SDS, glycine, Sequi-blot PVDF membranes (0.2
μm), Bradford reagent, broad range isoelectric focusing (IEF) Standards and Precision
Protein Standards were obtained from Bio-Rad (www.bio-rad.com). All other
electrophoresis supplies were obtained from GE-HealthCare (www.gehealthcare.com).
Deionized water (resistivity 18.2 MΩ/cm) was used for preparation of all solutions and
buffers. [U-14C]-4BP (42.6 Ci/mol, >98% radiochemical purity) was kindly provided by Dr.
Larry Hall (Bayer Crop Science) and mixed with unlabeled 4BP to a final specific activity of
8.05 Ci/mol. Chromatography paper 3MM was purchased from Whatman
(www.whatman.com).
Animals
All animal husbandry protocols were in accordance with the NIH Guide for the Care and
Use of Laboratory Animals.22 Experimental procedures were approved by the Institutional
Animal Care and Use Committee of the University of Kansas. Male Sprague-Dawley rats
from Charles River Laboratories (www.criver.com) were housed in a temperature and
humidity controlled room with a 12 h light/dark cycle and ad libitum access to food and
water.
Preparation of Subcellular Fractions of Liver Tissue
After acclimating for at least 3 days, animals were given 3 daily ip injections of sodium
phenobarbital (80 mg/kg) in 0.9% saline (1.0 mL/kg) in order to induce cytochrome P450
2B1/2 and increase 4BP metabolism and the yield of covalent adducts. After the third dose
the animals weighed 224–268 g. Food was withheld overnight and the next morning four
animals were injected with [14C]-4BP (8.05 mCi/mmol, 1 mmol/kg, ip) in corn oil (2.4 mL/
kg). Five hr after injection the animals were anesthetized by CO2 narcosis and killed by
decapitation. Their livers (41 g wet weight total) were removed and subcellular fractions
isolated essentially as described by Koen et al.19, 20 The livers were rinsed with ice-cold
buffer A (50 mM potassium phosphate buffer, pH 7.4, containing 0.15 M KCl, 5 mM EDTA
and 1 mM phenylmethanesulfonyl fluoride), weighed, and then minced with scissors and
homogenized in buffer A (4 mL/g tissue). The homogenates were pooled and centrifuged at
800 × g for 10 min. The resulting pellet was discarded, and the supernatant was further
centrifuged at 9,000 × g for 20 min, to give a pellet (P9-fraction or crude mitochondria) and
supernatant S9. The P9-fraction was resuspended in buffer A and centrifuged at 6,500 × g
for 20 min. The resulting pellet was resuspended in buffer B (100 mM potassium phosphate,
pH 7.4, containing 0.5 mM EDTA, 0.5 mM DTT and 20% glycerol), to obtain a final
mitochondrial sample. The S9-fraction (above) was further centrifuged at 12,000 × g for 20
min; the resulting pellet was discarded, and supernatant (S12) was centrifuged at 100,000 ×
g for 60 min, to obtain a pellet P100 (microsomes) and supernatant S100 (cytosol). The
microsomal fraction was further purified by resuspending in 0.1 M sodium pyrophosphate
buffer, pH 8.2 (1.3 mL/g original tissue weight), followed by centrifugation at 100,000 × g;
the final microsomal pellet was resuspended in buffer B. The cytosol fraction was purified
by re-centrifugation at 100,000 × g followed by dialysis against 20 mM potassium
phosphate (pH 7.4), 0.2 mM DTT, to remove soluble radiolabel. Protein CVB in rat liver
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fractions in vivo was determined as described earlier.19, 20, 23 All final samples were stored
in small aliquots at −80°C.
Two-Dimensional Electrophoresis, Phosphorimaging and In-gel Digestion
These procedures were carried out essentially as described earlier.19–21
Mass-Spectrometry of Tryptic Digests and Protein Identification
Of the 52 digest samples, half were analyzed by matrix-assisted laser desorption-ionization
time-of-flight (MALDI-TOF/TOF) MS on a Proteomics Analyzer 4700 (Applied
Biosystems, www.appliedbiosystems.com/) as described.19 The other half of the samples
were submitted to a capillary LC-MS/MS using an LTQ-FT hybrid linear quadrupole ion
trap Fourier transform ion cyclotron resonance (FT-ICR) mass spectrometer
(ThermoFinnigan, Bremen, Germany) as described.23 Raw data files were processed using
BioWorks 3.2 software followed by peptide/protein identification using Sequest
(ThermoFinnigan), Mascot (Matrix Science, version 2.2) and X! Tandem
(www.thegpm.org) database-searching programs with the IPI rat 20080908 database (40041
entries) with a fragment ion mass tolerance of 0.20 Da and a parent ion tolerance of 10.0
PPM. S-Pyridylethyl (+105), bromophenyl (+154), and bromohydroquinone (+186)
derivatives of cysteine residues were specified as variable modifications. Scaffold software
(Proteome Software Inc., version 2.06) was used to combine and validate MS/MS based
peptide and protein identifications. Peptide identifications with greater than 50% probability
as specified by the Peptide Prophet algorithm24 were accepted for reporting protein
coverage.
Preparation and Incubation of Isolated Hepatocytes
Hepatocytes from non-induced male Sprague-Dawley rats (175–275 g) were isolated using a
previously described protocol.25 Initial cell viability (85–95%) was assessed using trypan
blue exclusion. After isolation cells were transferred to medium A (DMEM supplemented
with 5% FBS, 1% (v/v) Pen-Strep, insulin (4 mg/L), 100 nM dexamethasone, and 2 mM L-
glutamine). For metabolism studies 4BP (0.2 mM) was incubated with 4.0 × 106 freshly
isolated rat hepatocytes suspended in medium A (2.0 mL) with or without inhibitors of
glucuronidation/sulfation in 50 mL round bottom screw-cap culture tubes. Incubations were
shaken at 100 Hz at 37 °C under an atmosphere of oxygen:carbon dioxide (95:5) for 2 hr.
Aliquots (150 μL) were removed at 0, 10, 20, 30, 40, 60, 90 and 120 min and added to 150
μL of cold acetonitrile. After centrifuging for 5 min at 2,000 × g the supernatant was
removed and stored at −20 °C until LC-MS/MS analysis. Incubations were repeated a
minimum of three times using different batches of hepatocytes.
For covalent binding studies, hepatocytes (2.4–4.0 × 106 live cells/mL) were incubated with
[14C]-BP (0.05–0.2 mM) in medium A lacking the FBS in 16 × 100 mm screw-capped glass
culture tubes in a final volume of 0.5 mL, at 37 °C for 90 min. In some cases 7HC (0.5
mM), borneol (0.45 mM) or DGN (2 mM) were added as inhibitors of glucuronidation/
sulfation. At 0, 10, 20, 30 and 90 min incubations were quenched by adding 55 μL of an
aqueous solution containing 10% Triton X-100 and 5 mM 4BP, and placing the tubes on ice.
For analysis of CVB in incubated hepatocytes we applied the principle of protein
precipitation on filter paper.26, 27 Aliquots (100 μL) of quenched incubations were applied
on 12 × 80 mm strips of absorbent paper 3MM. After drying briefly in air the strips were
washed by immersion for 10–15 min in each of a series of four baths (ca. 250 mL each)
comprised of 10% TCA, 95% ethanol, 95% ethanol again, and finally ethyl acetate. The
strips were then dried in air and submitted to liquid scintillation counting. CVB is reported
as pmol-equiv./mg protein.
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Freshly isolated hepatocytes were plated on duplicate collagen-coated 6-well plates at a
density of 7×105 live cells/well in 2.0 mL of medium A as noted above. After holding the
plates for 3 h at 37 °C in a CO2 incubator to allow attachment, the cells were washed twice
with pre-warmed phosphate-buffered saline (PBS, pH 7.4). After attachment, cell viability
was >98% according to Hoechst/PI staining. Incubations were started by adding solutions of
4BP and/or inhibitors in pre-warmed medium B (WME supplemented with 1% ITS, 1%
Pen-Strep, 2 mM L-glutamine, and 100 nM dexamethasone; 3 mL/well) and returning the
plates to the incubator. At appropriate times aliquots of culture medium (100 μL) were
removed for analysis of LDH according to the assay kit manufacturer’s directions, but with
all volumes reduced by half. For measurement of total cellular LDH content, 200 μL of 10%
Triton X-100 was added directly to wells containing untreated cells immediately after the
attachment period.
For time-lapse photomicrography freshly isolated cells were allowed to attach for 3 hr in
collagen-coated wells (300,000 live cells/well in a 12-well plate) in medium A (1 mL/well).
Cells were then washed twice with pre-warmed PBS and incubations were started by adding
pre-warmed medium B (1 mL/well) with or without 4BP (0.2 mM). Plates were observed
and photographed using an Olympus IX-81 epi-fluorescence microscope with a computer-
controlled mechanical stage, automated shutter and filters (Sutter Instrument), temperature,
humidity, and CO2 control. Images were collected every 10 minutes for 18 hr using a 20X
objective with a numerical aperture of 0.45 (Olympus), an EMCCD camera (Hamamatsu
Photonics) and the Slidebook image acquisition and processing package (Intelligent Imaging
Innovations). After the last photo the cells were stained with Hoechst 33342 and propidium
iodide to assess the live/dead ratio. The collected images (ca. 110 total) were then compiled
into movies at a playback speed of 0.3 sec/frame.
LC-MS/MS Analysis of 4BP and Its Metabolites
The LC-MS/MS system consisted of a Waters (Milford, MA) Acquity UPLC with a
Micromass (Manchester, UK) Quattro Ultima triple quadrupole mass spectrometer equipped
with an electrospray ionization interface. Chromatographic separation was performed on an
Intersil ODS-3 column (2.1 × 50 mm, 5 μm, GL Sciences, Inc.). The mobile phase consisted
of solvent A (15 mM ammonium acetate in 0.1% formic acid in water) and solvent B (15
mM ammonium acetate and 0.1% formic acid in CH3CN/water (10:1 v/v). The gradient
started at 1% solvent B for 0.5 min, increased linearly to 95% solvent B for 4.5 min, was
held for 95% solvent B for 1.0 min, and then returned to the starting composition over 4
min. For all MS analyses, the electrospray block and the desolvation temperatures were set
at 100° and 250°, respectively. The cone voltage was 25V, Q1 and Q3 resolution were set to
0.8u FWHH and for MS/MS collision energy was 20 eV for 4BP conjugates and 5 eV for
phenols. For analysis of 4BP and its phase II metabolites, the mass spectrometer was
operated in negative mode. 4BP, 4BP-glucuronide, 4BP-sulfate and 4-chlorophenol (internal
standard) were quantitatively analyzed in multiple reaction monitoring mode (MRM) using
the following transitions: m/z 171.0 → 171.0, 346.9 → 171.0, 250.9 → 171.0 and 127.0 →
127.0, respectively. The bromine isotope pattern was utilized to qualitatively confirm the
identity of 4BP, 4BP-glucuronide and 4BP-sulfate using transitions: m/z 173.0 → 173.0,
348.9 → 173.0 and 252.9 → 173.0, respectively. The unusual use of MRM to analyze 4BP
and 4-chlorophenol was due to the fact that these analytes did not fragment efficiently and
thus gave only weak signals in traditional MRM while in Q1-only mode high backgrounds
resulted in poor S/N ratios. However, transmitting their intact precursor ions in MRM mode
afforded very good S/N ratios. Calibration curves for 4BP were prepared by plotting the
appropriate peak area ratios of analyte/internal standard against the known concentrations
(2.5–100 μM) of 4BP in blank incubation medium using a linear regression with 1/x
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weighting using the Waters Quanlynx data processing tool. For detection and
characterization of GSH-trapped reactive metabolites of 4BP, we first used a precursors of
m/z 272 negative ion scan with further structural identification accomplished by product ion
scan in positive mode.28
Results and Discussion
Isolation and Identification of Rat Liver Proteins Adducted by Metabolites of [14C]-4-
Bromophenol
Five hr after ip injection of [14C]-4BP (1 mmol/kg body wt) a homogenate of liver tissue
contained 0.83 μCi 14C/g liver wet weight. After stepwise centrifugation to isolate
mitochondria, microsomes and cytosol, these fractions were found to contain covalently
bound 14C corresponding to 0.25, 0.33 and 0.42 nmol-eq. 4BP/mg protein. For comparison,
in a similar experiment with [14C]-BB we previously observed the level of covalent binding
in these fractions to be 6.1, 3.5 and 3.9 nmol-eq./mg protein, respectively (Table 2).20 We
were surprised that the CVB we observed with 4BP was not much higher given 1) the large
dose of 4BP that we used, and 2) the prior report of Monks et al.17 indicating that the CVB
of 4BP in vivo was 62% of that resulting from an equimolar dose of BB.
Despite the low total yield of covalent binding, aliquots of the three subcellular fractions
were subjected to 2D gel electrophoresis (4–6 gels/fraction). After Coomassie staining, the
gels of the mitochondrial, microsomal and cytosolic fractions revealed ca. 500, 200 and 800
protein spots, respectively (see Supporting Information). Radioactive protein spots on the
2D gels were located by phosphorimaging a polyvinylidene difluoride transblot of one gel
from each subcellular fraction. A total of 17, 9 and 21 weakly radioactive spots were
observed in mitochondrial, microsomal and cytosolic fractions, respectively. The
corresponding spots on the replicate Coomassie-stained gels were excised, pooled and
processed for tryptic digestion as described previously.19, 20, 23 We also excised and
analyzed a number of other spots corresponding to familiar and relatively abundant
“landmark” proteins (e.g. [Cu, Zn]-superoxide dismutase, cytochrome b5, aldehyde
dehydrogenase 2 and others) to ensure good registry of spot locations from one gel to the
next. Twenty nine of the 47 radioactive spots contained only one detectable protein.
However, these 29 spots comprised only 14 non-redundant target proteins because several of
these spots contained the same protein appearing in multiple spots of the same apparent
molecular weight but different apparent pI. This phenomenon is commonly observed in the
2D gel analysis of hepatocellular proteins.19, 20, 29, 30 As indicated in Table 1, all the
proteins listed were observed as a single protein in at least one spot, even though many of
them were also observed in other spots mixed with other proteins.
Since 4BP is not hepatotoxic in rats, it was suggested that the covalent labeling of proteins
by its oxidative metabolites is not toxicologically significant.17 It was therefore of interest to
identify these proteins and compare them to the proteins targeted by BB (which is
hepatotoxic). Of the 14 proteins identified in Table 1, nine were previously identified as
targets of BB metabolites in rat liver. This is perhaps not surprising since 4BP is a
significant metabolite of BB comprising 21–36% of total metabolites depending on the
dose.7 The important distinction, however, is that while 4BP can be oxidized further to
electrophilic quinone metabolites, 4BP can not revert back to BB-3,4-oxide, the putative
toxic metabolite of BB. In earlier studies we found direct evidence for the alkylation of
cysteine and histidine side chains by bromobenzene-2,3- and -3,4-epoxides,31, 32 but it was
clear that the vast majority of the identifiable adducts present were in fact quinone
derived.33–35 In the present work with 4BP we observed many tryptic peptides derived from
target proteins but none of them carried detectable 4BP-derived adducts. Nevertheless, there
can be little doubt that the adducts formed from 4BP are quinone-derived. In view of the low
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net covalent binding of 4BP, the similarity of its target protein profile to that of BB, and the
major role for quinone metabolites in protein adduction from both compounds, we began to
speculate that the non-toxicity of 4BP might be more a function of its low extent of adduct
formation rather than an intrinsic lack of adduct toxicity. We will return to this point later in
the manuscript.
Of the 4BP target proteins that we identified, three were from the mitochondrial fraction,
three were from the microsomal fraction and eight were found in the cytosolic fraction. Six
of these proteins are known to function in connection with protein maturation or
stabilization within the cell, four are enzymes of intermediary metabolism, and three
function in defense against electrophiles and peroxides. The final protein, albumin, is a
plasma protein well known for its ability to bind non-covalently many lipophilic molecules,
both xenobiotic and endogenous. It is synthesized in the liver in large quantities and
exported through the endoplasmic reticulum. This may explain why it is observed as a target
protein in liver, even though the vast majority of albumin in the body is found in the
bloodstream.
As shown in Table 1, most of the 4BP target proteins listed are also known to be targets for
electrophilic metabolites of several other xenobiotics.36 For example, the endoplasmic
reticulum lumenal proteins PDI A1 and PDI A3 are known as targets for reactive
metabolites for 13 other compounds. Overall, a total of 18 different agents, nearly all of
which are metabolically activated pro-hepatotoxins, target one or more of the 14 targets
listed in Table 1. It is interesting to ask whether some of these frequently targeted proteins
could serve as harbingers or “biomarkers” for potential cytotoxicity due to reactive
metabolites. This is a difficult question to answer for many reasons, not the least of which is
the general absence of target protein data for “negative control” compounds, i.e., compounds
that covalently bind relatively extensively but are truly non-toxic. We are aware of only one
well-documented example of such a compound, namely, the meta isomer of acetaminophen
(3-hydroxyacetanilide).37 It was thought that 4BP might be such a compound, but as
discussed below, this view requires re-consideration.
Since we observed only low levels of covalent binding from 4BP in vivo, we reexamined the
original comparison of its covalent binding to that of bromobenzene.17 As shown in Table 2
(lines 1 vs. 4), the net covalent binding of 4BP was ca. 62% that of BB. However, by
comparison to numerous other measurements of bromobenzene covalent
binding,3, 4, 20, 31, 32, 38, 39 the value in line 4 of Table 2 appears to be too low by as much as
a factor of 10. Because the toxic effects of reactive metabolites generally correlate with their
degree of covalent binding, it appeared that the lack of toxicity observed for exogenously
administered 4BP might be due to the fact that it produces very little covalent binding, rather
than to its adducts being intrinsically non-toxic. We further hypothesized that the low
binding of 4BP could be due to efficient glucuronidation and/or sulfation in preference to
oxidation to reactive quinone metabolites (see Scheme 1). In other words, the introduction of
the hydroxyl group to BB may ablate its toxicity by directing its metabolism toward
conjugation (detoxication) rather than oxidation (bioactivation). As an example of this,
phenylthiourea is metabolized by S-oxidation to a very potent pneumotoxin, but its p-
hydroxyphenyl analog is at least five times less toxic and its major metabolites are the
glucuronide and sulfate conjugates rather than oxidative desulfurization products.40
Similarly, while the hepatotoxicity of thiobenzamide is greatly increased by electron-
donating methyl or methoxy substituents in the meta or para positions,41 p-
hydroxythiobenzamide is essentially non-toxic despite the strong electron-donating effect of
the p-OH group.42 Conversely, pretreatment of hamsters with a regimen of 3-
methylcholanthrene (to induce P450), borneol (to inhibit glucuronidation and sulfation) and
diethyl maleate (to deplete glutathione), greatly potentiates the covalent binding and
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hepatotoxicity of acetaminophen.43 Thus, it is reasonable to propose that rapid
glucuronidation and/or sulfation of 4BP could seriously limit its metabolic activation and
covalent binding and thereby thwart its potential toxicity.
Metabolism, Covalent Binding and Toxicity of 4-Bromophenol in Isolated Hepatocytes
In view of the uncertainties noted above in regard to the relative covalent binding of 4BP vs.
BB in vivo, we sought to examine the toxicity of 4BP using isolated hepatocyte systems in
which the metabolism, covalent binding and toxicity of BB has been thoroughtly
studied.5, 44 As shown by the LDH release assay data in Figure 1, 4BP is definitely toxic to
isolated hepatocytes in a time- and concentration-dependent manner. As the concentration of
4BP in the medium increases from 0.1 mM to 0.5 mM, the onset of toxicity becomes earlier
and the overall severity greater. Time-lapse photomicrography (see Supporting Information)
shows that hepatocytes exposed to 0.2 mM 4BP undergo dramatic changes in their
morphology and their inter- and intracellular motility. Over a period of hours the attached
cells reverse their tendency to spread and establish cell-cell contacts and instead begin to
contract, round up, extend numerous and sometimes quite large cytoplasmic protrusions
(blebs) and finally become shriveled and motionless. By this time Hoechst/PI staining shows
that essentially all of the cells are stained by PI even though LDH release is not yet
maximal.
We next examined whether inhibitors of glucuronidation and/or sulfation would potentiate
the toxicity of 4BP by increasing its availability within the cell for further oxidation to
reactive quinone intermediates as implied by Scheme 1. (−)-Borneol and 7HC are both
alternate substrate inhibitors of glucuronidation that are well tolerated in vivo45–47 while
DGN blocks the synthesis of the UDP-glucuronic acid cosubstrate required for glucuronide
formation.48 The latter can be toxic at higher concentration over longer times, but we found,
as did Moldeus et al.,45 that 2 mM DGN was well tolerated by hepatocytes (Figure 2A).
Figures 2B-2D show the effect of these three inhibitors on the toxicity of 4BP to isolated rat
hepatocytes. At a concentration of 0.1 mM, 4BP shows little if any toxicity as measured by
LDH release, but in the presence of the inhibitors its toxicity becomes apparent (Figure 2B).
As the concentration of 4BP increases to 0.2 or 0.3 mM (Figures 2C and 2D), its toxicity
becomes increasingly apparent and the potentiation of its toxicity by the conjugation
inhibitors becomes more pronounced.
To verify that the glucuronidation inhibitors actually decreased the conjugation of 4BP
hepatocytes were incubated in suspension and the supernatant sampled and analyzed by LC-
MS/MS. Putative metabolite peaks were identified by manual surveys of LC/MS data and
confirmed by MS/MS analysis of fragmentation patterns in positive and/or negative ion
mode. Briefly, glucuronide conjugates showed strong neutral loss ions at [M-176]− while
sulfates were monitored by [M-80]− ions, as shown by the composite “MRM
chromatogram” in Figure S4. To monitor quantitatively the disappearance of 4BP during
incubations an internal standard (4-chlorophenol) was added to aliquots of incubation
medium withdrawn at various times.
As shown in Figure 3A, 4BP (initial concentration 0.2 mM) was completely consumed over
the course of a 2 hour incubation, and its disappearance followed first order kinetics
throughout (0.026 min−1). The addition of either 7HC or borneol slowed the rate
considerably (to 0.0061 and 0.0086 min−1, respectively). Borneol depressed the rate of
glucuronidation of 4BP to almost the same degree as 7HC (Figure 3B), but was noticeably
less effective than 7HC at inhibiting the sulfation of 4BP (Figure 3C). Increasing the sulfate
concentration in the medium from the basal level of 0.9 mM to 10 mM by adding sodium
sulfate had no effect, indicating that the availability of sulfate was not rate limiting (data not
shown).
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Because we had hypothesized that inhibiting the conjugation of 4BP would make it more
available for oxidation to reactive metabolites (viz. Scheme 1), we also searched the
incubation media by LC/MS for glutathione conjugates derived from 4BP. In addition to
manual examination of the data we scanned in negative ion mode for precursors of m/z =
272 (corresponding to the tripeptide γ-glutamyl-dehydroalanyl-glycine), as this
fragmentation is diagnostic for GSH conjugates.28, 49 In the LC/MS analysis of the medium
from incubation of 4BP alone, a negative ion scan for parents of m/z 272 showed a small
peak of ion current at ca. 2.9 min retention time. The negative ion mass spectrum of the
eluate under this peak showed peaks of m/z = 506 and 508 suggestive of a bromine-
containing molecule corresponding to the composition [4BP + O + GSH + CH2 − 2H],
derived by the 4-electron oxidation of 4BP to 4-bromo-1,2-benzoquinone followed by
Michael addition of GSH and methylation of the resulting catechol moiety (Scheme 2).
Bromophenols are known to deplete glutathione in hepatocytes50 and the unmethylated form
of this bromoquinone-GSH adduct was previously observed in microsomal incubations with
4BP.51 Positive ion scans for products of m/z 508 and 510 (MH+ for 79Br and 81Br,
respectively) showed identical fragmentation patterns that confirmed this structural
assignment (Figure S5) but did not allow us to determine which oxygen was methylated. A
related example of the COMT-mediated methylation of a catechol moiety in a large complex
polar metabolite was reported by Xie et al.52 To quantitate the relative amount of this
metabolite in the incubations we generated MRM chromatograms for the transitions m/z 508
→ 362 and m/z510 → 364 (see Figure S5) and integrated the peaks. These integrals showed
that adding borneol, 7HC or both to the incubation medium increased the amount of this
GSH-trapped reactive metabolite by factors of 2.3-, 5.2- and 5.7-fold, respectively. In
parallel with the increased glutathione trapping of a reactive quinone metabolite when
glucuronidation and sulfation are inhibited, 7HC and DGN increase the net covalent binding
of 4BP to cellular proteins as shown in Figure 4. This increase parallels the increases in
cytotoxicity observed when 4BP conjugation is inhibited (Figure 2). Although borneol
potentiated the toxicity of 4BP it did not increase the CVB under the conditions tested. In
contrast DGN increased the CVB of BP but only weakly potentiated toxicity, whereas 7HC
clearly potentiated both. These differences probably reflect the intrinsic complexity of the
metabolic pathways leading to bioactivation vs. detoxication (Scheme 1), and the relative
concentration, Km and Ki values for the various compounds being investigated, but more
significantly, they emphasize the importance of using multiple probes when attempting to
manipulate specific enzymes in complex systems like hepatocytes.
Summary
4BP, which is not hepatotoxic in the rat, was reported to undergo metabolic activation and
covalent binding only 38% less than an equimolar (but decidedly hepatotoxic) dose of its
metabolic precursor BB.17 This observation was interpreted to suggest that the covalent
binding derived from 4BP metabolites was not toxicologically significant. BB metabolites
covalently modify at least 45 liver proteins in vivo.36 By identifying proteins also targeted
by reactive metabolites of 4BP, we sought to reduce the size and complexity of the list of
BB targets and thereby focus attention on those proteins whose modification was more
likely to be associated causally with the toxicity of BB. After administering a large dose of
[14C]-4BP to rats, we observed only very low levels of covalent binding. Nevertheless, we
were able to identify single proteins in 29 radioactive spots on 2D gels of the mitochondrial,
microsomal and cytosolic fractions of rat liver. These 29 spots comprised only 14 non-
redundant proteins, nine of which were already known as targets of reactive BB metabolites.
Re-examination of earlier literature (Table 2) indicated that the value for BB covalent
binding reported by Monks et al.17 was much lower than other published values. Compared
to this low value (but not to other published values) the covalent binding of 4BP appeared to
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be comparatively high, which in turn lead to the erroneous conclusion that adducts derived
from 4BP were not toxic like those of BB.
In isolated hepatocytes and presumably in vivo, 4BP undergoes rapid conjugation by
glucuronidation and sulfation. These processes compete with 4BP oxidation to reactive
quinone metabolites, thus limiting its covalent binding and thereby also limiting its toxicity.
However, when these conjugating pathways are inhibited, the clearance of 4BP is markedly
decreased, the formation of glutathione conjugates of reactive quinone metabolites of 4BP
rises almost 6-fold, and both protein covalent binding and cytotoxicity increase
substantially. We therefore suggest that the main reason that 4BP is not significantly
hepatotoxic is not that protein adduction by its reactive metabolites is not harmful, but rather
that 4BP simply doesn’t give rise to very much covalent binding in vivo because of its rapid
conjugation. As demonstrated above, 4BP is definitely cytotoxic at moderately low
concentrations, and treatments that block its conjugation both increase its covalent binding
and potentiate its cytotoxicity. These results support the hypothesis that most covalent
binding probably does have toxicological consequences, if the extent to which it occurs
reaches a high enough level. Evidently that level is not reached by metabolites of 4BP
following its exogenous administration to rats.
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Toxicity of 4BP to isolated rat hepatocytes. Plated cells were washed as described in
Materials and Methods and then incubated with the indicated concentrations of 4BP.
Untreated (UT) control cells were incubated in medium lacking 4BP. At the indicated times
aliquots of medium were withdrawn for analysis of LDH leakage.
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Effect of conjugation inhibitors on the toxicity of 4BP to isolated rat hepatocytes. Plated
cells were washed as described in Materials and Methods and then incubated with the
indicated concentrations of 4BP ± inhibitors. Untreated (UT) control cells were incubated in
medium lacking 4BP and inhibitors. At the indicated times aliquots of medium were
withdrawn for analysis of LDH leakage. A) Effect of inhibitors alone. B–D) Effect of
inhibitors on increasing concentrations of 4BP.
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Effects of (−)-borneol and 7-hydroxycoumarin on glucuronidation and sulfation of 4BP by
isolated rat hepatocytes. 4BP (0.2 mM) was incubated with 4 × 106 hepatocytes in 2 mL
medium, either alone or with 0.5 mM borneol or 0.5 mM 7HC. A) Disappearance of 4-
bromophenol. B) Formation of 4-bromophenyl glucuronide. C) Formation of 4-bromophenyl
sulfate.
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Effect of glucuronidation inhibitors on covalent binding of 4BP (50 μM; specific activity
8.05 Ci/mol) in isolated hepatocytes (1.25 × 106 cells suspended in 0.5 mL medium). Data
shown are the mean ± SD (n=3). Compared to 4BP alone, the increases caused by 7-HC and
DGN are significant (p < 0.01).
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Metabolism and covalent binding of bromobenzene and 4-bromophenol.
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Structure and mass spectral fragmentation of glutathione-trapped reactive metabolite of 4BP.
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